LIFE.ME

Farmsintez PAO [LIFE.ME] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

LIFE.ME Stock Summary

In the News

LIFE.ME Financial details

Company Rating
-
Market Cap
1.36B
Income
-56.83M
Revenue
247.67M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
119
Optionable
No
Shortable
Yes
Earnings
-
P/E
-6.54
Forward P/E
-
PEG
0.69
P/S
3.57
P/B
11.2
P/C
-
P/FCF
-198.75
Quick Ratio
0.01
Current Ratio
0.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.13
EPS next Y
-
EPS next Q
-
EPS this Y
-70.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
6.15%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
30.49%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-16%
ROE
-89%
ROC
-0.84%
Gross Margin
21%
Oper. Margin
-36%
Profit Margin
-55%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.905-4.9
52W High
+5.5%
52W Low
+40.67%
RSI
46.07
Rel Volume
-
Avg Volume
-
Volume
2.16M
Perf Week
-3.65%
Perf Month
-1.4%
Perf Quarter
-
Perf Half Y
19.55%
-
-
-
-
Beta
-0.026
-
-
Volatility
0.11%, 0.16%
Prev Close
2.93%
Price
4.22
Change
0.48%

Something similar

Top by Market Cap
TSLA
1YD.DE
VTI
VFINX
BRH.DE
Same Sector
0QLQ.L
300595.SZ
CURR
4571.T
THTX
Check Those
ZMI.TO
PAMC
SAIL.NS
002562.SZ
BIG.L
Similar Market Cap
RNW
AGL
CMG.TO
SICAGEN.NS
CTIC

Company Profile

Healthcare Biotechnology
  • Market Capitalization 1.36B
  • Employee 119
  • CEO Mr. Petr Vladimirovich Kurglyakov
  • Headquarters Saint Petersburg,RU
  • IPO Date 2010-11-25
  • Website https://www.pharmsynthez.com

Public Joint-Stock Company ‘Pharmsynthez', a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez' has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia. Public Joint-Stock Company ‘Pharmsynthez' was founded in 1996 and is based in St. Petersburg, Russia.